Drug Profile
Lu AF82422
Alternative Names: Lu-AF82422Latest Information Update: 07 Mar 2024
Price :
$50
*
At a glance
- Originator Genmab; Lundbeck A/S
- Developer Lundbeck A/S
- Class Antibodies; Antiparkinsonians; Monoclonal antibodies
- Mechanism of Action Alpha-synuclein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Multiple system atrophy
- No development reported Parkinson's disease